Objectives: Describe some clinical features of gastric cancer stage IV; Evaluate overall survival (OS), progression free survival (PFS), and toxicity of first-line treatment ECX and EOX on stage IV gastric cancer patients. Methods: The retroprospective study was performed on 68 patients who were diagnosed stage IV gastric adenocarcinoma and have got ECX or EOX first line chemotherapy from 1/2008 to 6/2012 in Binh Dan hosptial.